Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02168777 |
Title | Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer |
Recruitment | Terminated |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Bayer |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |